

EXHIBIT 8

From: [Bundesen, Liza \(NIH/OD\) \[E\]](#)
 To: [Bull, Michelle G. \(NIH/OD\) \[E\]](#)
 Cc: [Jacobs, Anne \(NIH/OD\) \[E\]](#)
 Subject: FW: Grants for immediate termination today
 Date: Friday, February 28, 2025 7:46:09 PM
 Attachments: [M1 Termination Letter SR21HD107311-02.docx](#)

Hi Michelle,
 As we discussed, there are 5 more projects, listed immediately below. I think one is the AHRQ grant you mentioned earlier. Rachel is trying to work on the letters (see an example attached), but please handle as you see fit.
 I'm going drive home soon myself, but I'll log back on.
 I appreciate you,
 Liza

From: Riley, Rachel (OS/ASA)
 Sent: Friday, February 28, 2025 7:34 PM
 To: Bundesen, Liza (NIH/OD) [E] ; McElroy, James (NIH/OD) [E]
 Subject: RE: Grants for immediate termination today
 (LETTER ATTACHED)

5 grants:

An intervention to promote healthy relationships among transgender and gender expansive youth – 5R21HD107311-02 (DRAFT LETTER ATTACHED)
 Antigen discovery for transmission-blocking vaccines in Plasmodium vivax - 5R01AI150533-05 (I WILL DO NOW)
 China Health and Retirement Longitudinal study - 5R01AG037031-14 (I WILL DO NOW)
 Trans-HealthGUIDE: Transforming Health for Gender-Diverse Young Adults Using Interventions to Drive Equity = 5U01MH136558-03
 Using telehealth to improve access to gender-affirming care for BIPOC and rural gender diverse youth - 5K08HS029028-02

From: Riley, Rachel (OS/ASA)
 Sent: Friday, February 28, 2025 7:27 PM
 To: Bundesen, Liza (NIH/OD) [E] <lbundese@mail.nih.gov>; McElroy, James (NIH/NIMH) [E] <james.mcelroy@nih.gov>
 Subject: RE: Grants for immediate termination today
 First letter attached.

From: Riley, Rachel (OS/ASA)
 Sent: Friday, February 28, 2025 7:18 PM
 To: Bundesen, Liza (NIH/OD) [E] <lbundese@mail.nih.gov>; McElroy, James (NIH/NIMH) [E] <james.mcelroy@nih.gov>
 Subject: RE: Grants for immediate termination today

NIH GRANTS 002296

PRIVILEGED, CONFIDENTIAL, PRE-DECISIONAL

Dr. Ronna Popkin
4800 Sand Point Way NE
Seattle Children's Hospital
Seattle, WA

Dr. Popkin:

Funding for Project Number 5R21HD107311-02 is hereby terminated pursuant to the 2024 National Institutes of Health ("NIH") Grants Policy Statement,¹ and 2 C.F.R. § 200.340(a)(2) (2024). This letter constitutes a notice of termination.²

The 2024 Policy Statement applies to your project because NIH approved your grant on September 1, 2023, and "obligations generally should be determined by reference to the law in effect when the grants were made."³

The 2024 Policy Statement "includes the terms and conditions of NIH grants and cooperative agreements and is incorporated by reference in all NIH grant and cooperative agreement awards."⁴ According to the Policy Statement, "NIH may ... terminate the grant in whole or in part as outlined in 2 CFR Part 200.340."⁵ At the time your grant was issued, 2 C.F.R. § 200.340(a)(2) permitted termination "[b]y the Federal awarding agency or pass-through entity, to the greatest extent authorized by law, if an award no longer effectuates the program goals or agency priorities."

This award no longer effectuates agency priorities. NIH is obligated to carefully steward grant awards to ensure taxpayer dollars are used in ways that benefit the American people and improve their quality of life. Your project does not satisfy these criteria. Transgender issues: Research programs based on gender identity are often unscientific, have little identifiable return on investment, and do nothing to enhance the health of many Americans. Many such studies ignore, rather than seriously examine, biological realities. It is the policy of NIH not to prioritize these research programs.

Although "NIH generally will suspend (rather than immediately terminate) a grant and allow the recipient an opportunity to take appropriate corrective action before NIH makes a termination decision,"⁶ no corrective action is possible here. The premise of Project Number 5R21HD107311-02 is incompatible with agency priorities, and no modification of the project could align the project with agency priorities.

¹ <https://grants.nih.gov/grants/policy/nihgps/nihgps.pdf>.

² 2 C.F.R. § 200.341(a); 45 C.F.R. § 75.373

³ *Bennett v. New Jersey*, 470 U.S. 632, 638 (1985).

⁴ 2024 Policy Statement at IIA-1.

⁵ *Id.* at IIA-155.

⁶ 2024 Policy Statement at IIA-156.

PRIVILEGED, CONFIDENTIAL, PRE-DECISIONAL

Costs resulting from financial obligations incurred after termination are not allowable.⁷ Nothing in this notice excuses either NIH or you from complying with the closeout obligations imposed by 2 C.F.R. §§ 75.381-75.390. NIH will provide any information required by the Federal Funding Accountability and Transparency Act or the Office of Management and Budget's regulations to *USAspending.gov*.⁸

Administrative Appeal

You may object and provide information and documentation challenging this termination.⁹ NIH has established a first-level grant appeal procedure that must be exhausted before you may file an appeal with the Departmental Appeals Board.¹⁰

You must submit a request for such review to Dr. Matthew Memoli no later than 30 days after the written notification of the determination is received, except that if you show good cause why an extension of time should be granted, Dr. Matthew Memoli may grant an extension of time.¹¹

The request for review must include a copy of the adverse determination, must identify the issue(s) in dispute, and must contain a full statement of your position with respect to such issue(s) and the pertinent facts and reasons in support of your position. In addition to the required written statement, you shall provide copies of any documents supporting your claim.¹²

Sincerely,

[insert sig block]

⁷ See 2 C.F.R. § 200.343 (2024).

⁸ 2 C.F.R. § 200.341(c); 45 C.F.R. § 75.373(c).

⁹ See 45 C.F.R. § 75.374.

¹⁰ See 42 C.F.R. Part 50, Subpart D.

¹¹ *Id.* § 50.406(a).

¹² *Id.* § 50.406(b).